Albiglutide: First Global Approval
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Albiglutide (Eperzan® [EU]; Tanzeum™ [US]), a glucagon-like peptide 1 receptor agonist, has been developed by GlaxoSmithKline for the treatment of type 2 diabetes mellitus (T2DM). Albiglutide has received its first global approval in this indication in the EU, for use in combination with other antihyperglycaemic agents, including basal insulin, when these drugs and diet and exercise do not provide adequate glycaemic control, and as monotherapy in patients unable to take metformin due to contraindications or intolerance when diet and exercise alone do not provide adequate glycaemic control. Albiglutide has subsequently been approved for the second-line or later treatment of T2DM as an adjunct to diet and exercise in the US. This article summarizes the milestones in the development of albiglutide leading to this first approval for the treatment of T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The half-life of albiglutide is approximately 4 to 7 days.102”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [102]
Citations
Cites
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 386 · cited 4×
“Decreased glucose excursion and increase insulin secretion were seen in wild-type but not GLP-1R-/- mice treated with albiglutide, indicating that it mimics the actions of native GLP1 [15].”
InfluentialPratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70214-6 · Cited by 326 · cited 1×
“Albiglutide did not demonstrate non-inferiority to liraglutide for the primary endpoint of HbA1c reduction at 32 weeks in the Harmony 7 trial [39].”
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Rosenstock, J., Reusch, J., Bush, M., Yang, F., Stewart, M., & for the Albiglutide Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0366 · Cited by 237 · cited 2×
“The most frequent AEs occurring in higher proportions of patients treated with albiglutide than in the Clinical trials of albiglutide conducted by GlaxoSmithKline Drugs Indication Study phase Status Study locations Trial identifiers Albiglutide, pioglitazone, metformin T2DM III Completed US, India, Peru, South Africa,…”
Ahrén, B., Johnson, S. L., Stewart, M., Cirkel, D. T., Yang, F., Perry, C., & Feinglos, M. N. (2014) · Diabetes Care · doi:10.2337/dc14-0024 · Cited by 228
Meier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
Bush, M. A., Matthews, J. E., De Boever, E. H., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Gutierrez, M., & Stewart, M. W. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00992.x · Cited by 181 · cited 2×
“A phase I study showed that albiglutide was suitable for once-weekly dosing [14].”
Lorenz, M., Evers, A., & Wagner, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.022 · Cited by 127 · cited 2×
“The half-life of native GLP-1 is short (approximately 1–2 minutes) due to rapid degradation by dipeptidylpeptidase 4 (DPP-4), making it unsuitable as a treatment for type 2 diabetes mellitus [2, 3].”
Nauck, M. A., Stewart, M. W., Perkins, C., Jones-Leone, A., Yang, F., Perry, C., Reinhardt, R. R., & Rendell, M. (2016) · Diabetologia · doi:10.1007/s00125-015-3795-1 · Cited by 125
Reusch, J. E. B., Stewart, M. W., Perkins, C. M., Cirkel, D. T., Ye, J., Perry, C., Reinhardt, R., & Bode, B. W. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12382 · Cited by 122
Bao, W., Aravindhan, K., Alsaid, H., Chendrimada, T., Szapacs, M., Citerone, D. R., Harpel, M. R., Willette, R. N., Lepore, J. J., & Jucker, B. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023570 · Cited by 105 · cited 1×
“and improve haemodynamics, cardiac function and cardiac energetic parameters in a rat model of myocardial ischaemia and reperfusion [16].”
Research works printed but not linked: 6
- Bush MA, Smith C, Watanalumlerd P, et al. Population pharmacokinetic (PK) analysis of albiglutide in a phase iib study in Japanese patients with type 2 diabetes. Diabetes. 2012;61:A261–2.
- Fonseca VL, Ahren B, Chow F, et al. Once weekly GLP-1 receptor agonist albiglutide vs prandial lispro added to basal glargine in type 2 diabetes: similar glycaemic control with weight loss and less hypoglycaemia. Diabetologia. 2012;55:S241.
- Pratley RE, Barnett A, Feinglos MM, et al. Efficacy and safety of once-weekly (QW) albiglutide vs. once-daily (QD) liraglutide in type 2 diabetes (T2D) inadequately controlled on oral agents: Harmony 7 trial. Diabetes. 2012;61:A240–1.
- Martin AA, Johnson SL, Ye J, et al. Improved treatment satisfaction with weekly abiglutide vs. Thrice daily prandial insulin added to insulin glargine in type 2 diabetes. Diabetes. 2013;62:A659.
- Martin AA, Johnson SL, Ye J, et al. Treatment satisfaction with albiglutide and liraglutide in patients with type 2 diabetes uncontrolled with oral therapy. Diabetes. 2013;62:A259–60.
- Seino Y, Inagaki N, Miyahara H, et al. Albiglutide significantly lowers glycemia in japanese patients with type 2 diabetes (T2D). Diabetes. 2012;61:A248.
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Albumin-based drug delivery: harnessing nature to cure disease
Larsen, M. T., Kuhlmann, M., Hvam, M. L., & Howard, K. A. (2016) · Molecular and Cellular Therapies · doi:10.1186/s40591-016-0048-8 · Cited by 683
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669
“The recently FDA-approved drug, albiglutide, is a DPPIV-resistant GLP-1 dimer fused to human albumin and has a half-life of 6–7 days, which enables weekly dosing for the treatment of type 2 diabetics (110,111).”
BackgroundThe Neonatal Fc Receptor (FcRn): A Misnomer?
Pyzik, M., Sand, K. M. K., Hubbard, J. J., Andersen, J. T., Sandlie, I., & Blumberg, R. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01540 · Cited by 429
Sand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304
Metadata
- Authors
- Poole, R. M., & Nowlan, M. L.
- Corresponding author
- Nowlan, Mary L.
- ORCID
- Nowlan, Mary L.
- Venue
- Drugs
- Published
- 2014-05-27
- Volume
- 74
- Issue
- 8
- Pages
- 929-938
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2084245396
- Cited by
- 49
- References
- 18
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 7 · 2023: 1 · 2022: 7 · 2021: 2 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 5 · 2015: 4 · 2014: 5
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- albiglutide, type 2 diabetes, GLP-1 receptor agonists, drug approval, antidiabetic drugs, metformin intolerance, glycemic control, drug development milestones
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Humans, Hypoglycemic Agents, Drug Approval, Receptors, Glucagon, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Albiglutide: First Global Approval. https://app.cochat.ai/papers/10.1007/s40265-014-0228-2
- The paper
- Poole, R. M., & Nowlan, M. L. (2014). Albiglutide: First Global Approval. Drugs. https://doi.org/10.1007/s40265-014-0228-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.